A 3-month-old boy is brought to the physician by his parents because of a 2-day history of poor feeding and lethargy. He was born at term and has had three episodes of bilateral otitis media since birth. Umbilical cord separation occurred at the age of 8 weeks. He is at the 30th percentile for height and 20th percentile for weight. His temperature is 39.0°C (102.2°F) and blood pressure is 58/36 mm Hg. Physical examination shows white oral patches and confluent scaly erythematous skin lesions in the groin. Laboratory studies show a leukocyte count of 41,300/mm3 (92% segmented neutrophils and 8% lymphocytes) and a platelet count of 224,000/mm3. Blood cultures at 20°C (68°F) grow catalase-positive yeast cells. Which of the following is the most likely underlying cause of this patient's symptoms? Which of the following is the most likely diagnosis? (Choice A) A defective CD40 ligand is the underlying mechanism of type 1 hyper-IgM syndrome, which typically manifests with recurrent infections during the first 2 years of life. However, neutropenia rather than neutrophilia is typically seen, and patients often show failure to thrive. Delayed umbilical cord separation would also not be expected. (Choice B) Leukocyte adhesion deficiency type 1 (LAD1) is caused by an autosomal recessive defect in CD18 (beta-2 integrin), which prevents leukocyte migration to the site of infection. As a result, patients have recurrent mucocutaneous infections that can progress to sepsis and a characteristic absence of pus or neutrophils at the site of infection. Other features of the condition include poor wound healing with large skin ulcers, delayed separation of the umbilical cord due to omphalitis, and severe periodontitis/gingivitis. A very high neutrophil count (as high as 100,000/mm3 during active infection) is seen because neutrophil activation and recruitment of neutrophils from the non-circulating pool occurs. However, neutrophils are unable to extravasate into tissues, causing pooling within the circulation. LAD1 is diagnosed using flow cytometric measurement of surface molecules such as CD11b or CD18. The treatment for mild to moderate cases is mainly supportive, with early treatment of infections and prophylaxis with trimethoprim-sulfamethoxazole if needed, but severe cases require definitive therapy with hematopoietic stem cell transplantation. (Choice C) A defect in the interleukin-2 receptor subunit gamma gene (IL2RG) is the most common mutation associated with severe combined immunodeficiency (SCID), which can manifest soon after birth with recurrent episodes of otitis media, candidiasis, and sepsis. However, patients would also typically show failure to thrive and have a history of chronic diarrhea. A CBC, moreover, would reveal a low absolute lymphocyte count (< 1000/mm3). Delayed umbilical cord separation would not be expected. (Choice D) A defect in Bruton tyrosine kinase (BTK) is responsible for X-linked agammaglobulinemia (XLA), which may result in recurrent otitis media from infection with extracellular bacteria such as S. pneumoniae and H. influenzae. However, infants with B-cell defects such as XLA typically do not develop symptoms before 3–6 months because they generally retain passively acquired maternal antibodies up to this age. Delayed umbilical cord separation would also not **wait

Reading File
Finding Sources
Finding Sources
The answer is Choice B — Leukocyte Adhesion Deficiency Type 1 (LAD1).
Here is the full breakdown of the clinical reasoning:

Diagnosis: Leukocyte Adhesion Deficiency Type 1 (LAD1)

Underlying Mechanism

LAD1 is caused by an autosomal recessive defect in CD18 (the β2-integrin subunit), which is the shared β-chain of three leukocyte integrins: LFA-1 (CD11a/CD18), Mac-1 (CD11b/CD18), and p150,95 (CD11c/CD18). Without functional CD18, neutrophils cannot perform the tight adhesion step required to extravasate from blood vessels into infected tissues. — Cellular and Molecular Immunology; Harrison's Principles of Internal Medicine

How This Case Maps to LAD1

Clinical FeatureExplanation in LAD1
Delayed umbilical cord separation (8 weeks)Classic hallmark; neutrophils cannot migrate into the cord stump to clear bacteria (normal separation is 1–2 weeks)
Recurrent infections since birth (3× otitis media)Neutrophils can be recruited but cannot leave the bloodstream to fight infection at mucosal/tissue sites
Oral candidiasis (white patches) + groin dermatitisRecurrent mucocutaneous infections with both bacteria and fungi due to absent neutrophil tissue infiltration
Markedly elevated WBC (41,300/mm³, 92% neutrophils)Neutrophils are activated and released from the marginating pool but cannot extravasate → pool in circulation, causing dramatic leukocytosis (can reach >100,000/mm³ during infection)
Catalase-positive yeast on blood culture at 20°CConsistent with Candida or Malassezia — organisms that normally require intact phagocyte defense
Sepsis (fever 39°C, BP 58/36)Infections rapidly progress to bacteremia/fungemia because tissue neutrophil defense is absent

Why the Other Choices Are Wrong

ChoiceDiagnosisWhy Excluded
AHyper-IgM syndrome (CD40L defect)Causes neutropenia, not neutrophilia; no delayed cord separation
CSCID (IL2RG defect)Lymphopenia expected (lymphocytes <1,000/mm³); this patient has 8% lymphocytes but the absolute count from 41,300 × 8% ≈ 3,300 — above the SCID threshold; no delayed cord separation
DX-linked agammaglobulinemia (BTK defect)Symptoms do not appear before 3–6 months due to maternal antibody protection; this infant is already symptomatic at 3 months with cord separation delay and candidiasis — inconsistent with pure B-cell defect

Key Diagnostic Test

Flow cytometry measuring CD11b or CD18 surface expression on neutrophils — absent or severely reduced in LAD1.

Treatment

  • Mild–moderate: prophylactic trimethoprim-sulfamethoxazole, aggressive infection treatment
  • Severe (as in this case): hematopoietic stem cell transplantation (only cure)

delayed separation of the umbilical cord due to omphalitis, and severe periodontitis/gingivitis. A very high neutrophil count (as high as 100,000/mm3 during active infection) is seen because neutrophil activation and recruitment of neutrophils from the non-circulating pool occurs. However, neutrophils are unable to extravasate into tissues, causing pooling within the circulation. LAD1 is diagnosed using flow cytometric measurement of surface molecules such as CD11b or CD18. The treatment for mild to moderate cases is mainly supportive, with early treatment of infections and prophylaxis with trimethoprim-sulfamethoxazole if needed, but severe cases require definitive therapy with hematopoietic stem cell transplantation. (Choice C) A defect in the interleukin-2 receptor subunit gamma gene (IL2RG) is the most common mutation associated with severe combined immunodeficiency (SCID), which can manifest soon after birth with recurrent episodes of otitis media, candidiasis, and sepsis. However, patients would also typically show failure to thrive and have a history of chronic diarrhea. A CBC, moreover, would reveal a low absolute lymphocyte count (< 1000/mm3). Delayed umbilical cord separation would not be expected. (Choice D) A defect in Bruton tyrosine kinase (BTK) is responsible for X-linked agammaglobulinemia (XLA), which may result in recurrent otitis media from infection with extracellular bacteria such as S. pneumoniae and H. influenzae. However, infants with B-cell defects such as XLA typically do not develop symptoms before 3–6 months because they generally retain passively acquired maternal antibodies up to this age. Delayed umbilical cord separation would also not be expected. Moreover, candidiasis is more commonly seen in defects involving T cells and granulocytes than in isolated primary defects of antibody production such as XLA. (Choice E) Defective NADPH oxidase results in chronic granulomatous disease (CGD), which may manifest in infancy with candidiasis (since C. albicans is catalase-positive) and neutrophilia during episodes of infection. However, these infections tend to remain localized, and sepsis is not as common as in other primary immune deficiency syndromes. Other pathognomonic features of CGD include GI obstruction and urinary retention caused by granulomas. Delayed umbilical cord separation would not be expected. (Choice F) Defective microtubules due to a loss of function of the lysosomal trafficking regulator gene (LYST) is the underlying pathophysiology of Chediak-Higashi syndrome (CHS), which can result in systemic candidiasis. However, patients with CHS would have neutropenia, not neutrophilia. Features such as oculocutaneous albinism and/or ocular motility disorders (e.g., strabismus, nystagmus) would also be present. Delayed umbilical cord separation would not be expected. (Choice G) A defectively organized actin cytoskeleton due to a mutation in the WAS gene is the underlying cause of Wiskott-Aldrich syndrome (WAS), which can manifest in infancy with recurrent otitis media as well as scaly erythematous lesions in the diaper area due to atopic dermatitis. However, the absence of thrombocytopenia on a CBC essentially rules out WAS. Delayed umbilical cord separation would also not be expected. above 2 msgs merge and make hy usmle style topper level notes hy to revise the whole concept from the above question and option distractors ruling out

USMLE High-Yield Notes: Primary Immunodeficiencies

Rapid Revision from Clinical Vignette + Distractor Analysis


THE ANCHOR VIGNETTE (Pattern Recognition)

3-month-old boy | recurrent bilateral otitis media since birth | umbilical cord separation at 8 weeks | oral candidiasis + groin dermatitis | sepsis | WBC 41,300 (92% neutrophils) | blood culture → catalase-positive yeast
Diagnosis: Leukocyte Adhesion Deficiency Type 1 (LAD1)

MASTER COMPARISON TABLE

FeatureLAD1Hyper-IgM (CD40L)SCID (IL2RG)XLA (BTK)CGD (NADPH)Chediak-Higashi (LYST)Wiskott-Aldrich (WAS)
Gene/DefectCD18 (β2-integrin)CD40L (CD154)IL2RG (γc chain)BTKNADPH oxidaseLYST (lysosomal trafficking)WASp (actin cytoskeleton)
InheritanceARXLXLXLXL (most common)ARXL
Neutrophil countVery HIGH (↑↑↑)Low (neutropenia)Low (lymphopenia; neutrophils nl)NormalHigh during infectionLowNormal/Low
Lymphocyte countNormalNormal/↓Very LOW (<1000)Normal (no B cells)NormalNormalNormal/↓
Delayed cord separationYESNoNoNoNoNoNo
Catalase+ organism susceptibilityYes (Candida)NoYesNoYes (Aspergillus, Candida, Staph, Burkholderia)PartialNo
CandidiasisYesNoYesRare (T-cell intact)YesYesNo
Recurrent otitis mediaYesYesYesYes (S. pneumo, H. flu)Less commonLess commonYes
Onset of symptomsBirth1st yearBirth3–6 months (maternal Ab)InfancyInfancyInfancy
ThrombocytopeniaNoNoNoNoNoNoYES ✅ (small platelets)
Skin findingsMucocutaneous infections, no pusNone specificDiffuse infectionsNone specificGranulomasOculocutaneous albinismEczema/atopic derm
Pathognomonic featureDelayed cord; no pus at infection site; extreme leukocytosisOpportunistic + bacterial infections; low IgG/A/E, high IgMFailure to thrive, chronic diarrheaAbsent B cells/tonsilsGI/urinary granulomas; lymphadenopathyAlbinism + nystagmus/strabismus + giant granules in neutrophilsTriad: eczema + thrombocytopenia + immunodeficiency
DiagnosisFlow cytometry (↓ CD11b/CD18)Serum Ig levels; ↑ IgM, ↓ restFlow cytometry (absent T/B/NK)Flow cytometry (absent B cells)DHR flow cytometry / NBT testPeripheral smear (giant granules)CBC (↓ small platelets) + genetic
Definitive TxHSCT (severe)HSCTHSCTIVIG + antibioticsHSCT (severe) / IFN-γ (mild)HSCTHSCT

LAD1 — DEEP DIVE

Pathophysiology

Normal: Selectins → rolling → ICAM-1/LFA-1 → tight adhesion → diapedesis → tissue
LAD1:   Selectins → rolling → [CD18 ABSENT] → NO tight adhesion → neutrophils TRAPPED in blood
  • CD18 is the shared β2 subunit of 3 integrins: LFA-1 (CD11a/CD18), Mac-1 (CD11b/CD18), p150,95 (CD11c/CD18)
  • Without tight adhesion → no extravasation → no pus at infection sites → infections rage unchecked
  • Neutrophils accumulate in circulation → extreme leukocytosis (up to 100,000/mm³ during infection)

Classic Clinical Triad

  1. Delayed umbilical cord separation (>3 weeks; normally <2 weeks) — due to omphalitis without neutrophil response
  2. Recurrent mucocutaneous infections progressing to sepsis, no pus
  3. Marked neutrophilia even at baseline (3–5× normal); surges dramatically during infection

Organisms

  • Bacteria: S. aureus, gram-negatives (Pseudomonas, E. coli)
  • Fungi: Candida (note: also catalase-positive, grows at room temp)

Diagnosis

  • Flow cytometry: absent/reduced CD11b or CD18 surface expression on neutrophils
  • Severity graded by residual CD18 expression: <1% = severe; 1–10% = moderate

DISTRACTOR RULES — ELIMINATING WRONG ANSWERS

Rule 1: Delayed cord separation → ONLY LAD1

No other primary immunodeficiency causes delayed umbilical cord separation. If you see it → LAD1 immediately.

Rule 2: Neutrophil count is your sorting key

Neutrophil CountThink
Extremely HIGHLAD1, CGD (during infection)
Low (neutropenia)Hyper-IgM, Chediak-Higashi
NormalXLA, Wiskott-Aldrich
Not the key findingSCID (lymphopenia is the key)

Rule 3: Maternal antibody protection window = 3–6 months

  • XLA patients are asymptomatic until ~6 months (maternal IgG transferred transplacentally persists)
  • Any infant symptomatic from birth → cannot be XLA

Rule 4: Candidiasis implicates T-cell OR granulocyte defects, NOT isolated B-cell defects

  • Candidiasis = normal in XLA (intact T cells and neutrophils handle fungi)
  • Candidiasis in this case → rules out XLA as sole explanation

Rule 5: Thrombocytopenia (small platelets) = Wiskott-Aldrich until proven otherwise

  • Normal platelet count (224,000) here → rules out WAS immediately

Rule 6: Albinism + nystagmus/strabismus = Chediak-Higashi

  • Giant cytoplasmic granules on peripheral smear = pathognomonic
  • Chediak-Higashi = neutropenia (not neutrophilia)

Rule 7: Catalase-positive organisms + granulomas + GI/urinary obstruction = CGD

  • CGD: NADPH oxidase fails → can't generate reactive oxygen species → cannot kill catalase-positive bugs
  • CGD infections tend to be localized (forming granulomas), not rapidly septic like LAD1
  • CGD does NOT cause delayed cord separation

IMMUNOGLOBULIN PROFILE CHEAT SHEET

ConditionIgGIgMIgAIgE
Hyper-IgM syndrome↓↓↑↑↓↓↓↓
XLA↓↓↓↓↓↓↓↓
SCID↓↓↓↓↓↓↓↓
Wiskott-Aldrich↓ IgMNormal↑ IgA/IgE
LAD1NormalNormalNormalNormal
CGDNormalNormalNormalNormal

ONE-LINERS FOR RAPID RECALL

  • LAD1 = "Neutrophils stuck in traffic (bloodstream), can't get to the scene (tissues)" → no pus + extreme leukocytosis + delayed cord
  • Hyper-IgM = "Can't class-switch (no CD40L signal)" → high IgM, low everything else, Pneumocystis pneumonia, neutropenia
  • SCID = "No T cells, no immunity" → lymphopenia <1000, failure to thrive, chronic diarrhea, all infections
  • XLA = "No B cells, no antibodies, no problem until mom's antibodies run out at 6 months" → recurrent encapsulated bacteria
  • CGD = "Neutrophil gets there but can't kill catalase+ bugs" → granulomas, GI/urinary obstruction, NBT test flat
  • Chediak-Higashi = "Giant granules, albino look, can't coordinate lysosomes" → neutropenia + albinism + nystagmus
  • Wiskott-Aldrich = "WASted platelets, eczema, and immunity" → eczema + microthrombo-cytopenia + infections

HIGH-YIELD BUZZ WORDS → DIAGNOSIS

Buzz Word/FindingDiagnosis
Delayed umbilical cord separationLAD1
Extreme leukocytosis, no pus at infection sitesLAD1
High IgM, low IgG/IgA/IgEHyper-IgM
Lymphocyte count <1000, failure to thriveSCID
Symptoms begin after 6 months, encapsulated bacteriaXLA
Catalase+ infections + granulomas + GI obstructionCGD
Giant granules on smear + oculocutaneous albinismChediak-Higashi
Eczema + small platelets + recurrent infectionsWiskott-Aldrich
Absent tonsils/lymph nodes on examXLA
Pneumocystis in infancySCID or Hyper-IgM

too much to process hy compsact set of rules and concept please

Primary Immunodeficiencies — Compact USMLE Rules


STEP 1: Three Questions to Nail the Diagnosis

1. When did symptoms start?
  • Birth → LAD1, SCID, CGD, Chediak-Higashi
  • After 6 months → XLA (maternal Ab protection until then)
2. What is the neutrophil/lymphocyte count?
  • Neutrophils ↑↑↑ → LAD1, CGD
  • Neutrophils ↓ → Hyper-IgM, Chediak-Higashi
  • Lymphocytes ↓↓ (<1000) → SCID
3. Any pathognomonic finding?
  • Delayed cord separation → LAD1 (only one)
  • Small platelets + eczema → Wiskott-Aldrich
  • Albinism + nystagmus → Chediak-Higashi
  • High IgM, low rest → Hyper-IgM
  • No tonsils/lymph nodes → XLA
  • GI/urinary granulomas → CGD

THE 7 DISEASES IN 2 LINES EACH

DiseaseDefectKey Distinguisher
LAD1CD18 (β2-integrin)Delayed cord + no pus + extreme neutrophilia
Hyper-IgMCD40L↑IgM, ↓all others + neutropenia
SCIDIL2RG (γc chain)Lymphocytes <1000 + failure to thrive + chronic diarrhea
XLABTKAsymptomatic until 6 mo; no B cells/tonsils; encapsulated bacteria
CGDNADPH oxidaseCatalase+ bugs + granulomas + GI/urinary obstruction
Chediak-HigashiLYSTAlbinism + giant granules on smear + neutropenia
Wiskott-AldrichWASpEczema + micro-thrombocytopenia + infections (triad)

LAD1 CORE CONCEPT (This Question)

CD18 absent → no tight adhesion → neutrophils CAN'T leave blood
→ No pus at infection sites
→ Infections → rapid sepsis
→ Neutrophils pool in blood → WBC up to 100,000
→ Umbilical cord never cleared → separation delayed (>3 weeks)
Dx: Flow cytometry (↓ CD11b/CD18) Tx: Mild = TMP-SMX prophylaxis | Severe = HSCT

5 GOLDEN RULES

  1. Delayed cord separation = LAD1, nothing else
  2. Candidiasis = T-cell or granulocyte defect (not XLA — B-cell only)
  3. Neutrophilia + infections = LAD1 or CGD (everything else is neutropenia or normal)
  4. Platelets low = Wiskott-Aldrich (normal platelets rule it out instantly)
  5. Symptomatic at birth = never XLA (maternal Ab protect until 6 months)

but in this question the answer is b2 intergrin

Yes — and that is exactly what the notes say. There is no contradiction here.
CD18 = the β2-integrin subunit. They are the same thing, just named differently:
NameWhat it is
CD18The gene/protein name
β2-integrinThe structural/functional name
LAD1The disease caused by its deficiency
CD18 is the shared β2 subunit of three integrin heterodimers:
  • LFA-1 = CD11a/CD18
  • Mac-1 = CD11b/CD18
  • p150,95 = CD11c/CD18
So when a question says "defect in β2-integrin" and another says "defect in CD18" — they mean the exact same mutation causing the exact same disease: LAD1.
USMLE will use both terms interchangeably. Know both.

so can you So can you include such defects also in your high yield note, like you know defective beta-2 integrin, defective CD40 ligand, defective interleukin-2 receptor gamma chain, defective tyrosine kinase, defective NADPH oxidase, defective microtubules, defective actin cytoskeleton, all in which primary immune deficiencies can be related to. You can add that also in the above short mentioned high yield note. It will be very useful.

Primary Immunodeficiencies — Compact USMLE Rules (Updated)


THE 7 DISEASES: DEFECT → DISEASE → DISTINGUISHER

Molecular DefectProtein/GeneDiseaseKey Distinguisher
Defective β2-integrinCD18LAD1Delayed cord + no pus + extreme neutrophilia
Defective CD40 ligandCD154Hyper-IgM↑IgM, ↓all others + neutropenia
Defective IL-2 receptor γ-chainIL2RG (γc)SCIDLymphocytes <1000 + FTT + chronic diarrhea
Defective Bruton tyrosine kinaseBTKXLAAsymptomatic until 6 mo; no B cells/tonsils
Defective NADPH oxidaseCYBB (gp91)CGDCatalase+ bugs + granulomas + GI obstruction
Defective microtubule functionLYSTChediak-HigashiAlbinism + giant granules on smear + neutropenia
Defective actin cytoskeletonWASpWiskott-AldrichEczema + micro-thrombocytopenia + infections

STEP 1: THREE QUESTIONS TO NAIL THE DIAGNOSIS

1. When did symptoms start?
  • Birth → LAD1, SCID, CGD, Chediak-Higashi
  • After 6 months → XLA (maternal Ab protection until then)
2. What is the neutrophil/lymphocyte count?
  • Neutrophils ↑↑↑ → LAD1, CGD
  • Neutrophils ↓ → Hyper-IgM, Chediak-Higashi
  • Lymphocytes ↓↓ (<1000) → SCID
3. Any pathognomonic finding?
  • Delayed cord separation → LAD1 (only one)
  • Small platelets + eczema → Wiskott-Aldrich
  • Albinism + nystagmus → Chediak-Higashi
  • High IgM, low rest → Hyper-IgM
  • No tonsils/lymph nodes → XLA
  • GI/urinary granulomas → CGD

LAD1 CORE CONCEPT

CD18 (β2-integrin) absent
→ No tight adhesion → neutrophils CAN'T leave blood
→ No pus at infection sites → rapid sepsis
→ Neutrophils pool in blood → WBC up to 100,000
→ Umbilical cord never cleared → separation delayed (>3 weeks)
Dx: Flow cytometry (↓ CD11b/CD18) Tx: Mild = TMP-SMX | Severe = HSCT

IMMUNOGLOBULIN PROFILE (Quick Reference)

DiseaseIgGIgMIgA/IgE
Hyper-IgM↓↓↑↑↓↓
XLA↓↓↓↓↓↓
SCID↓↓↓↓↓↓
Wiskott-Aldrich↓ IgMNormal↑ IgA/IgE
LAD1 / CGD / ChediakNormalNormalNormal

5 GOLDEN RULES

  1. Delayed cord separation = LAD1, nothing else
  2. Candidiasis = T-cell or granulocyte defect — not XLA (B-cell only, T cells intact)
  3. Neutrophilia + infections = LAD1 or CGD — everything else is neutropenia or normal
  4. Platelets low = Wiskott-Aldrich — normal platelets rule it out instantly
  5. Symptomatic at birth = never XLA — maternal Ab protect until 6 months

DIAGNOSIS METHOD (All 7)

DiseaseDiagnostic Test
LAD1Flow cytometry → absent CD11b/CD18
Hyper-IgMSerum Ig levels (↑IgM, ↓rest)
SCIDFlow cytometry → absent T/B/NK cells
XLAFlow cytometry → absent B cells; no tonsils
CGDDHR flow cytometry or NBT test (no burst)
Chediak-HigashiPeripheral smear → giant granules in neutrophils
Wiskott-AldrichCBC → small, low platelets + genetic testing

A 2-year-old boy with a history of multiple hospitalizations for fever and infection undergoes immunologic evaluation. Serum CH50 assay shows inappropriately low erythrocyte lysis and further workup confirms C8 deficiency. This patient is at increased risk for recurrent infections with which of the following pathogens? Terminal complement deficiencies (C5–C9) impede the formation of the membrane attack complex, which renders affected patients more susceptible to Neisseria bacteremia (e.g., N. meningitidis and N. gonorrhoeae pyogenic infections). (Choice B) Individuals with an IgA deficiency (e.g., selective IgA deficiency or ataxia-telangiectasia) are at increased risk of Giardia lamblia infection. Giardiasis is not associated with terminal complement deficiency. (Choice C) Fungal infections, including Candida, are associated with impaired T-cell immunity and IL-17 defects. These can be detected by the absence of a reaction to cutaneous application of Candida antigen, or absent T-cell proliferation in vitro, but will not influence CH50 assay. Candida infections are not associated with terminal complement deficiency. (Choice D) Pneumocystis jirovecii infections are associated with hyper-IgM syndrome and significant T-cell dysfunction (e.g., in HIV). Hyper-IgM syndrome is characterized by decreased levels of IgG, IgA, and IgE, while IgM levels may be normal or increased. It does not influence CH50 assay, and Pneumocystis infections are not associated with terminal complement deficiency. (Choice E) Increased susceptibility to Nocardia and other catalase-positive species is seen in granulocyte deficiencies such as chronic granulomatous disease (CGD). CGD can be detected with flow cytometry (the tetrazolium dye reduction test is obsolete) but does not have an effect on CH50 assay. Nocardia infection is not associated with terminal complement deficiency. (Choice F) Mycobacterium infection is associated with decreased interferon gamma and interleukin-12 receptor deficiency. It is not associated with terminal complement deficiency. same as above HY compact question solving notes for usmle step `1 from above concepts and opton distractors

Complement Deficiencies + Pathogen Susceptibility — Compact USMLE Notes


THIS QUESTION: ONE RULE TO KNOW

Terminal complement deficiency (C5–C9)
→ No MAC formation
→ Can't kill encapsulated gram-negatives with outer membrane
→ Susceptible to NEISSERIA (meningitidis + gonorrhoeae) ONLY
Answer: Neisseria species

COMPLEMENT PATHWAY — DEFICIENCY MAP

Component DeficientDisease/ConsequenceKey Pathogen
C1, C2, C4 (classical)SLE-like autoimmune diseaseNot infection-focused
C3Recurrent ALL encapsulated bacteriaS. pneumo, H. flu, N. meningitidis
C5–C9 (terminal/MAC)Neisseria bacteremia specificallyN. meningitidis, N. gonorrhoeae
DAF/CD59Paroxysmal nocturnal hemoglobinuria (PNH)Hemolysis, not infection
MBLRecurrent infections in early childhoodEncapsulated bacteria
C1-esterase inhibitorHereditary angioedemaNo infection risk
Rule: C3 = broad encapsulated bacteria susceptibility. C5–C9 = Neisseria only.

PATHOGEN → IMMUNE DEFECT MASTER TABLE

PathogenImmune DefectDisease
NeisseriaTerminal complement (C5–C9) ↓MAC deficiency
Giardia lambliaIgA deficiencySelective IgA def / Ataxia-telangiectasia
CandidaT-cell defect / IL-17 defectSCID, DiGeorge, mucocutaneous candidiasis
Pneumocystis jiroveciiT-cell defect / CD40L defectSCID, Hyper-IgM, HIV
Nocardia + catalase+ bugsNADPH oxidase defectCGD
MycobacteriumIL-12 receptor / IFN-γ defectMendelian susceptibility to mycobacterial disease
S. pneumo, H. flu, N. meningitidisAntibody / C3 / Spleen absentXLA, C3 def, Asplenia
AspergillusNeutrophil defectCGD, post-chemo neutropenia
CryptosporidiumIgA deficiency / T-cell defectHyper-IgM (especially)

DIAGNOSTIC TEST → IMMUNE DEFECT

TestWhat It Detects
CH50 assay (low)Classical + terminal complement pathway defect
AH50 assay (low)Alternative complement pathway defect
Flow cytometry (CD11b/CD18)LAD1
DHR / NBT test (no burst)CGD (NADPH oxidase defect)
Serum Ig levelsXLA, Hyper-IgM, SCID
Cutaneous Candida antigen / T-cell proliferationT-cell dysfunction
Absent tonsils on examXLA
Key point: CGD and complement deficiencies are both detected by separate tests. CGD does NOT affect CH50. Complement deficiency does NOT affect NBT/DHR.

4 GOLDEN RULES FROM THIS QUESTION

  1. CH50 low = complement deficiency — if C5–C9 specifically → Neisseria is the answer, always
  2. Neisseria = terminal complement (MAC) — no other immune defect preferentially causes Neisseria
  3. Giardia = IgA deficiency — the gut secretory IgA connection
  4. Nocardia/catalase+ = CGD — granulocyte killing defect, never complement

ONE-LINERS

  • MAC (C5–C9) = "punches holes in Neisseria's outer membrane — without it, Neisseria survives"
  • C3 = "opsonin hub — deficiency = all encapsulated bacteria, not just Neisseria"
  • IgA = "mucosal guardian — deficiency = Giardia gets through gut"
  • CGD = "neutrophil arrives but can't kill — catalase+ bugs survive"
  • IL-12/IFN-γ axis = "macrophage activation for mycobacteria — deficiency = disseminated TB/NTM"

A 17-year-old girl comes to the physician because of a sore throat, fevers, and fatigue for the past 3 weeks. Her temperature is 37.8°C (100°F), pulse is 97/min, and blood pressure is 90/60 mm Hg. Examination of the head and neck shows cervical lymphadenopathy, pharyngeal erythema, enlarged tonsils with exudates, and palatal petechiae. The spleen is palpated 2 cm below the left costal margin. Her leukocyte count is 14,100/mm3 with 54% lymphocytes (12% atypical lymphocytes). Results of a heterophile agglutination test are positive. This patient is at increased risk for which of the following conditions?Rheumatic fever is a delayed inflammatory sequela of group A streptococcus (GAS) pharyngitis that typically affects individuals within 2–4 weeks of primary infection. While this patient has a sore throat as well as signs of pharyngitis and tonsillitis, she also presents with splenomegaly and has a positive heterophile agglutination test, which rather indicates infectious mononucleosis. (Choice B) Kaposi sarcoma is not caused by Epstein-Barr virus (human herpesvirus 4) responsible for this patient's mononucleosis, but a close relative, the human herpesvirus 8. However, both HHV-4 and HHV-8 are oncoviruses that can lead to malignancies. (Choice C) Risk factors for hepatocellular carcinoma (HCC) include viral hepatitis (primarily hepatitis B and C), chronic aflatoxin exposure, chronic alcohol use, and obesity. While viral hepatitis manifests with fatigue, as seen in this patient, patients would also experience signs of liver injury (abdominal pain, jaundice, and/or pruritus), which are absent in this patient. Furthermore, her pharyngitis, splenomegaly, and positive heterophile agglutination test are suggestive of infectious mononucleosis. HCC is not a complication of infectious mononucleosis. (Choice D) Hodgkin lymphoma (HL) is a potential complication of infectious mononucleosis caused by Epstein-Barr virus (EBV). Additional complications of EBV infection include non-Hodgkin lymphoma (e.g., Burkitt lymphoma, diffuse large B cell lymphoma, and primary CNS lymphoma in HIV-positive patients) and nasopharyngeal carcinoma. The pathophysiology of EBV-associated malignancy includes virus-induced expression of latent membrane protein 1 (LMP1), which constitutively activates NF-κB and kinases that drive cell proliferation. (Choice E) Mycotic aneurysms are a potential complication of infectious endocarditis or vascular trauma (e.g., intravenous drug use). Presentation varies depending on the anatomic location affected (e.g., peripheral aneurysm vs cerebral aneurysm). Although this patient has a fever, she has no abnormal cardiac findings or other signs of infectious endocarditis (e.g., Osler nodes or Janeway lesions). Furthermore, her pharyngitis, splenomegaly, and positive heterophile agglutination test are suggestive of infectious mononucleosis. Mycotic aneurysms are not a complication of EBV infection. notes as above

Infectious Mononucleosis (EBV) — Compact USMLE Notes


THIS QUESTION: DIAGNOSE FAST

FindingSignificance
Sore throat + fever + fatigueClassic triad of mono
Cervical lymphadenopathy + exudative tonsillitis + palatal petechiaeEBV pharyngitis pattern
SplenomegalyEBV dissemination
Atypical lymphocytes (12%)Reactive CD8+ T cells fighting EBV-infected B cells
Positive heterophile agglutination (Monospot)Confirms EBV/infectious mononucleosis
Answer: Hodgkin Lymphoma (EBV-associated malignancy)

EBV — CORE PATHOPHYSIOLOGY

EBV → infects B cells via CD21 (complement receptor)
→ B cells proliferate uncontrollably
→ CD8+ T cells react → atypical lymphocytes on smear
→ Latent infection persists lifelong
→ LMP1 protein → activates NF-κB → drives cell proliferation → MALIGNANCY

EBV-ASSOCIATED MALIGNANCIES (Must Know All)

MalignancyKey Detail
Hodgkin LymphomaReed-Sternberg cells; EBV most common trigger
Burkitt Lymphomat(8;14) MYC translocation; "starry sky" pattern; jaw mass in Africa
Diffuse Large B-Cell LymphomaAggressive; EBV-associated
Primary CNS LymphomaHIV/immunocompromised patients specifically
Nasopharyngeal CarcinomaSoutheast Asian predominance; EBV-driven
Mechanism for all: LMP1 → constitutive NF-κB activation → uncontrolled B-cell proliferation

EBV vs LOOK-ALIKES (Distractor Rules)

ConditionWhy NOT this answer
Rheumatic feverSequela of GAS (group A Strep), not EBV. Monospot negative in GAS.
Kaposi sarcomaHHV-8, not HHV-4 (EBV). Both are oncoviruses but different viruses.
Hepatocellular carcinomaHBV/HCV/alcohol/aflatoxin — not EBV. No jaundice here either.
Mycotic aneurysmComplication of infective endocarditis, not EBV. No cardiac findings here.

ONCOVIRUS CHEAT SHEET

VirusCancer(s)
EBV (HHV-4)Hodgkin lymphoma, Burkitt lymphoma, DLBCL, CNS lymphoma (HIV), nasopharyngeal CA
HHV-8Kaposi sarcoma, primary effusion lymphoma
HPV (16/18)Cervical CA, oropharyngeal CA, anal CA
HBV/HCVHepatocellular carcinoma
HTLV-1Adult T-cell leukemia/lymphoma
H. pyloriGastric adenocarcinoma, MALT lymphoma
MCPyVMerkel cell carcinoma

MONO COMPLICATIONS (High-Yield)

ComplicationKey Point
Splenic ruptureMost dangerous acute complication; avoid contact sports for 3–4 weeks
Airway obstructionMassive tonsillar enlargement; use steroids
Ampicillin/amoxicillin rashDiffuse maculopapular rash if given for "strep throat" misdiagnosis
Hodgkin/Burkitt lymphomaLong-term oncologic risk via LMP1/NF-κB
Guillain-Barré / encephalitisRare neurologic complications

4 GOLDEN RULES

  1. Atypical lymphocytes = reactive CD8+ T cells, not the infected cells (B cells are infected)
  2. Monospot positive = EBV — automatically think EBV malignancies as long-term risk
  3. Palatal petechiae + splenomegaly + atypical lymphocytes = EBV (not GAS, not CMV monospot+)
  4. Ampicillin/amoxicillin in mono = rash — never give penicillin-type without ruling out mono first

ONE-LINERS

  • EBV = "kisses B cells via CD21, CD8 T cells fight back → atypical lymphocytes on smear"
  • LMP1 = "EBV's oncogene — turns on NF-κB, turns off apoptosis → lymphoma"
  • HHV-8 vs HHV-4 = "8 = Kaposi, 4 = EBV lymphomas — same family, different cancers"
  • Monospot = "heterophile antibodies agglutinate sheep/horse RBCs — quick EBV screen"
  • Splenic rupture = "no sports, no abdominal palpation in mono — spleen is a time bomb"

A 68-year-old woman comes to the physician for a follow-up examination. Three months ago, she underwent heart transplantation for restrictive cardiomyopathy and was started on transplant rejection prophylaxis. Her pulse is 76/min and blood pressure is 148/82 mm Hg. Physical examination shows enlargement of the gum tissue. There is a well-healed scar on her chest. Serum studies show hyperlipidemia. The physician recommends removing a drug that decreases T cell activation by inhibiting the transcription of interleukin-2 from the patient's treatment regimen and replacing it with a different medication. Which of the following drugs is the most likely cause of the adverse effects seen in this patient?Sirolimus is an immunosuppressant drug that can be used for transplant rejection prophylaxis. It binds FK binding protein (FKBP) to form a complex that inhibits mTOR. This inhibition prevents activation of mTOR kinase, which leads to inhibition of interleukin-2 (IL-2) induced T cell proliferation and impaired B cell differentiation. Sirolimus does not inhibit the transcription of IL-2. Side effects of this drug include hypertension and hyperlipidemia, as seen in this patient. However, it is not known to cause gingival hyperplasia. Further important adverse effects of sirolimus include infection, malignancy, pancytopenia, and insulin resistance. (Choice B) Glucocorticoids such as prednisolone are commonly used for transplant rejection prophylaxis. They exert their immunosuppressant effect via various mechanisms of action, including inhibition of NF-κB, suppression of T cell proliferation, and induction of apoptosis in lymphocytes. Glucocorticoids have a wide range of side effects including hypertension and hyperlipidemia, as seen in this patient. However, this group of drugs is not known to cause gingival hyperplasia. (Choice C) Tacrolimus is an immunosuppressant drug that is commonly used for transplant rejection prophylaxis. It binds FK binding protein (FKBP) to form a complex that inhibits calcineurin. Inhibition of calcineurin blocks activation of the NFAT transcription factors, which prevents interleukin-2 transcription and, as a result, decreases T cell activation. Side effects of this drug include hypertension and hyperlipidemia, as seen in this patient. However, it is not known to cause gingival hyperplasia. Further important adverse effects instead include infection, malignancy, new-onset diabetes mellitus, nephrotoxicity, and neurotoxicity. Although the mechanism of action of tacrolimus is consistent with the drug that the physician recommended to remove from this patient's treatment regimen, the reported adverse effects are more likely caused by a different medication. (Choice D) Cyclosporine is an immunosuppressant drug that is commonly used for transplant rejection prophylaxis. It binds cyclophilin to form a complex that inhibits calcineurin. Inhibition of calcineurin blocks activation of the NFAT transcription factors, which prevents interleukin-2 transcription and, as a result, decreases T cell activation. Cyclosporine is the only calcineurin inhibitor to cause gingival hyperplasia, so it is most likely the drug that was used in this patient. Further important side effects of cyclosporine include increased susceptibility to infection and increased risk for malignancy. (Choice E) Azathioprine is an immunosuppressant drug that can be used for transplant rejection prophylaxis. Azathioprine is a precursor of 6-mercaptopurine, an antimetabolite that blocks purine synthesis

Transplant Immunosuppressants — Compact USMLE Notes


THIS QUESTION: SOLVE IN 3 STEPS

Clue 1: Drug "inhibits transcription of IL-2" → Calcineurin inhibitor (blocks NFAT) Clue 2: Calcineurin inhibitors = Cyclosporine OR Tacrolimus Clue 3: Gingival hyperplasia → Cyclosporine ONLY (not tacrolimus)
Answer: Cyclosporine

IMMUNOSUPPRESSANT MASTER TABLE

DrugBindsInhibitsMechanismUnique Side Effects
CyclosporineCyclophilinCalcineurin → ↓NFAT → ↓IL-2 transcription↓ T-cell activationGingival hyperplasia, nephrotoxicity, HTN, hyperlipidemia, hirsutism
TacrolimusFKBPCalcineurin → ↓NFAT → ↓IL-2 transcription↓ T-cell activationNew-onset DM, nephrotoxicity, neurotoxicity, HTN, hyperlipidemia — NO gingival hyperplasia
SirolimusFKBPmTOR → ↓IL-2 induced proliferation↓ T-cell proliferation (not transcription)HTN, hyperlipidemia, pancytopenia, insulin resistance — NO gingival hyperplasia
AzathioprinePurine synthesis (via 6-MP)↓ DNA synthesis → ↓ lymphocyte proliferationBone marrow suppression, pancreatitis
MycophenolateIMP dehydrogenase → ↓ purine synthesisLymphocyte-specific antiproliferativeGI upset, bone marrow suppression
GlucocorticoidsGRNF-κB, ↓ cytokines, apoptosis of lymphocytesBroad immunosuppressionCushingoid, HTN, hyperlipidemia, hyperglycemia — NO gingival hyperplasia
BasiliximabIL-2 receptor (CD25)Blocks IL-2 signalingHypersensitivity
OKT3 (Muromonab)CD3 on T cellsBlocks TCR signalingCytokine release syndrome

CALCINEURIN INHIBITORS SIDE BY SIDE

Cyclosporine:  Cyclophilin → calcineurin inhibited → ↓IL-2
Tacrolimus:    FKBP       → calcineurin inhibited → ↓IL-2
Sirolimus:     FKBP       → mTOR inhibited → ↓IL-2 effect (NOT transcription)
Key distinction: Sirolimus also binds FKBP but hits mTOR, NOT calcineurin. Question specifies "inhibits IL-2 transcription" → rules out sirolimus immediately.

GINGIVAL HYPERPLASIA — DRUG LIST (Must Know All 3)

DrugClass
CyclosporineImmunosuppressant
Nifedipine (CCB)Antihypertensive
PhenytoinAntiepileptic
Cyclosporine causes HTN → often co-prescribed with nifedipine → double gingival hyperplasia risk

NEPHROTOXICITY COMPARISON

DrugNephrotoxic?
CyclosporineYES (afferent arteriole vasoconstriction)
TacrolimusYES (same mechanism)
SirolimusLess nephrotoxic; often used to spare kidneys
Azathioprine/MMFNo direct nephrotoxicity

4 GOLDEN RULES

  1. Gingival hyperplasia = Cyclosporine (among immunosuppressants — also phenytoin, nifedipine)
  2. Inhibits IL-2 transcription = calcineurin inhibitor (cyclosporine or tacrolimus) — sirolimus inhibits IL-2 response, not transcription
  3. New-onset diabetes post-transplant = Tacrolimus (not cyclosporine)
  4. FKBP binds both tacrolimus AND sirolimus — but they hit different targets (calcineurin vs mTOR)

ONE-LINERS

  • Cyclosporine = "Cyclophilin → calcineurin block → no IL-2 → hairy gums, bad kidneys, hairy body"
  • Tacrolimus = "FK506 → FKBP → calcineurin block → no IL-2 → diabetogenic, neurotoxic, no gum growth"
  • Sirolimus = "Rapamycin → FKBP → mTOR block → T cells can't respond to IL-2 — no gums, no kidneys spared"
  • Azathioprine = "Prodrug → 6-MP → no purines → no DNA → no lymphocytes"
  • Gingival hyperplasia triad = "Cyclosporine, Nifedipine, Phenytoin — CNN"

an antimetabolite that blocks purine synthesis and subsequently inhibits the proliferation of lymphocytes. It does not inhibit the transcription of interleukin-2. Important adverse effects of azathioprine include bone marrow suppression (leading to pancytopenia), hepatotoxicity, acute pancreatitis, infection, malignancy, and fetal harm in pregnant women. Azathioprine is not known to cause any of the adverse effects observed in this patient. (Choice F) Mycophenolate mofetil is an immunosuppressant drug that is commonly used for transplant rejection prophylaxis. It inhibits inosine monophosphate dehydrogenase, which impairs lymphocyte purine synthesis and subsequently inhibits lymphocyte proliferation. Mycophenolate mofetil does not inhibit the transcription of interleukin-2. Side effects of this drug include hypertension and hyperlipidemia, as seen in this patient. However, it is not known to cause gingival hyperplasia. Further important adverse effects of mycophenolate mofetil include first-trimester pregnancy loss and congenital malformations, infection, malignancy, neutropenia, and hyperglycemia. this also include

The previous table already includes both Azathioprine and Mycophenolate. Here is the fully updated note with their complete side effect profiles added:

Transplant Immunosuppressants — Compact USMLE Notes (Final)


THIS QUESTION: SOLVE IN 3 STEPS

Clue 1: "Inhibits transcription of IL-2" → Calcineurin inhibitor (blocks NFAT) Clue 2: Calcineurin inhibitors = Cyclosporine OR Tacrolimus Clue 3: Gingival hyperplasia → Cyclosporine ONLY
Answer: Cyclosporine

IMMUNOSUPPRESSANT MASTER TABLE

DrugBindsInhibitsBlocks IL-2 transcription?Unique Side Effects
CyclosporineCyclophilinCalcineurin → ↓NFATYESGingival hyperplasia, nephrotoxicity, HTN, hyperlipidemia, hirsutism
TacrolimusFKBPCalcineurin → ↓NFATYESNew-onset DM, nephrotoxicity, neurotoxicity, HTN, hyperlipidemia — NO gingival hyperplasia
SirolimusFKBPmTOR → ↓IL-2 responseNO (blocks response, not transcription)HTN, hyperlipidemia, pancytopenia, insulin resistance — NO gingival hyperplasia
AzathioprinePurine synthesis (via 6-MP)NOBone marrow suppression, hepatotoxicity, pancreatitis, teratogenic — NO gingival hyperplasia
MycophenolateIMP dehydrogenase → ↓purinesNOHTN, hyperlipidemia, neutropenia, hyperglycemia, teratogenic (1st trimester loss + malformations) — NO gingival hyperplasia
GlucocorticoidsGRNF-κB, ↓ cytokinesNOCushingoid, HTN, hyperlipidemia, hyperglycemia — NO gingival hyperplasia
BasiliximabIL-2 receptor (CD25)NOHypersensitivity reactions

THE CRITICAL DISTINCTION

Cyclosporine  → Cyclophilin → calcineurin blocked → NFAT can't enter nucleus → NO IL-2 mRNA
Tacrolimus    → FKBP       → calcineurin blocked → NFAT can't enter nucleus → NO IL-2 mRNA
Sirolimus     → FKBP       → mTOR blocked        → IL-2 signal can't drive proliferation
Azathioprine  → 6-MP       → no purines          → no DNA synthesis → no lymphocyte division
Mycophenolate → IMPDH      → no purines          → no DNA synthesis → lymphocyte-specific
Azathioprine and Mycophenolate both block purine synthesis but via different enzymes. Neither touches IL-2 transcription.

TERATOGEN ALERT (Transplant Drugs)

DrugFetal Risk
Mycophenolate1st trimester loss + congenital malformations — stop before pregnancy
AzathioprineFetal harm — avoid in pregnancy
SirolimusAvoid in pregnancy
Tacrolimus/CyclosporineUse with caution — relatively safer options if transplant essential

GINGIVAL HYPERPLASIA TRIAD — "CNN"

DrugClass
CyclosporineImmunosuppressant
Nifedipine (CCB)Antihypertensive
Nifedipine is often co-prescribed with cyclosporine → doubles the risk
PhenytoinAntiepileptic
Mnemonic: "Can Nifedipine Phyte?" = Cyclosporine, Nifedipine, Phenytoin

SIDE EFFECT QUICK SORT

Side EffectDrug(s)
Gingival hyperplasiaCyclosporine, Nifedipine, Phenytoin
New-onset diabetesTacrolimus, glucocorticoids, sirolimus
NephrotoxicityCyclosporine, Tacrolimus
PancreatitisAzathioprine
Bone marrow suppressionAzathioprine, mycophenolate (neutropenia)
TeratogenicityMycophenolate (most dangerous), azathioprine
HTN + hyperlipidemiaCyclosporine, tacrolimus, sirolimus, MMF, glucocorticoids
HirsutismCyclosporine
NeurotoxicityTacrolimus

5 GOLDEN RULES

  1. Gingival hyperplasia = Cyclosporine (among immunosuppressants)
  2. IL-2 transcription blocked = calcineurin inhibitor — cyclosporine or tacrolimus
  3. Sirolimus binds FKBP like tacrolimus but hits mTOR, not calcineurin — does NOT block IL-2 transcription
  4. Pancreatitis = Azathioprine (not the others)
  5. Teratogen = Mycophenolate (most dangerous; 1st trimester loss + malformations)

ONE-LINERS

  • Cyclosporine = "Cyclophilin-calcineurin-NFAT-IL2 — hairy gums, hairy body, bad kidneys"
  • Tacrolimus = "Same target as cyclosporine (calcineurin) but via FKBP — diabetogenic, neurotoxic, clean gums"
  • Sirolimus = "FKBP like tacrolimus but hits mTOR — blocks IL-2 response not transcription"
  • Azathioprine = "6-MP blocks purines — pancreatitis and marrow suppression are its signatures"
  • Mycophenolate = "IMPDH → lymphocyte-selective purine block — dangerous in pregnancy"
This is a shared conversation. Sign in to Orris to start your own chat.